Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Position Lowered by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC decreased its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 6.0% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 10,266 shares of the specialty pharmaceutical company’s stock after selling 656 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Jazz Pharmaceuticals were worth $1,144,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Versant Capital Management Inc lifted its holdings in Jazz Pharmaceuticals by 13,450.0% in the second quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company’s stock worth $29,000 after acquiring an additional 269 shares during the last quarter. Itau Unibanco Holding S.A. bought a new position in Jazz Pharmaceuticals in the second quarter worth about $29,000. EverSource Wealth Advisors LLC lifted its holdings in Jazz Pharmaceuticals by 55.1% in the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock worth $30,000 after acquiring an additional 97 shares during the last quarter. GAMMA Investing LLC lifted its holdings in Jazz Pharmaceuticals by 65.5% in the second quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock worth $31,000 after acquiring an additional 116 shares during the last quarter. Finally, Gladius Capital Management LP bought a new position in Jazz Pharmaceuticals in the second quarter worth about $33,000. Institutional investors own 89.14% of the company’s stock.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, SVP Mary Elizabeth Henderson sold 1,410 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $108.30, for a total value of $152,703.00. Following the transaction, the senior vice president now owns 14,531 shares in the company, valued at approximately $1,573,707.30. The trade was a 8.85 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Neena M. Patil sold 3,700 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $123.41, for a total transaction of $456,617.00. Following the completion of the transaction, the executive vice president now owns 33,048 shares in the company, valued at approximately $4,078,453.68. This trade represents a 10.07 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 6,110 shares of company stock worth $720,160 over the last quarter. 4.20% of the stock is currently owned by company insiders.

Jazz Pharmaceuticals Price Performance

NASDAQ JAZZ opened at $121.65 on Friday. Jazz Pharmaceuticals plc has a 12 month low of $99.06 and a 12 month high of $134.17. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The firm has a market capitalization of $7.35 billion, a PE ratio of 17.13, a P/E/G ratio of 1.07 and a beta of 0.57. The company’s 50 day simple moving average is $112.22 and its 200 day simple moving average is $110.35.

Wall Street Analyst Weigh In

JAZZ has been the topic of a number of recent research reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $140.00 target price on shares of Jazz Pharmaceuticals in a report on Monday, September 9th. HC Wainwright reaffirmed a “buy” rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, August 1st. Piper Sandler cut their price target on Jazz Pharmaceuticals from $188.00 to $166.00 and set an “overweight” rating on the stock in a report on Thursday, August 1st. TD Cowen cut their price target on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. Finally, Robert W. Baird cut their price target on Jazz Pharmaceuticals from $160.00 to $154.00 and set an “outperform” rating on the stock in a report on Thursday, August 1st. Three analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $175.00.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.